$537.65
Today
as of Jul 22, 16:51 ET
Last 30 days
Recent Press Releases & News
BofA Securities Adjusts Price Target on Madrigal Pharmaceuticals to $553 From $542
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals Insider Sold Shares Worth $1,368,253, According to a Recent SEC Filing
Overview
52-week range
$272
$615
77% of range
Avg surprise (last 3)
+21.2%
Avg reaction (last 2)
+2.8%
50% positive
Latest IV / EM
58%
EM ±13.4% · $540 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Wed May 6, 2026 | Mar/2026 | $-3.25 | $-3.61 | +10.0% | +2.1% | +7.4% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-4.01 | — | — | — | — | financials |
| Tue Aug 5, 2025 | Jun/2025 | $-1.90 | $-3.48 | +45.4% | — | — | earnings |
| Thu May 1, 2025 | Mar/2025 | $-3.32 | $-3.62 | +8.3% | — | -1.9% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-4.92 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-7.10 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-7.38 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-5.34 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-4.69 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Jul 30, 2026 | Jun/2026 | BMO | -$2.66 | -$1.90 | -40.0% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $137M | — | — | — |
| Cost of revenue | — | — | — | — | $5M | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-93M | — | $-114M | $-47M | $-79M | — | $-116M | $-163M |
| Net income | $-94M | — | $-114M | $-42M | $-73M | — | $-107M | $-152M |
| EPS (diluted) | $-3.25 | — | $-4.01 | $-1.50 | $-2.61 | — | $-4.92 | $-7.10 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $227M | $199M | $296M | $186M | $184M | $100M | $233M | $495M |
| Inventory | $112M | $75M | $69M | $63M | $55M | $34M | $9M | $7M |
| Total current assets | $1.18B | $1.25B | $1.35B | $1.00B | $988M | $1.03B | $1.06B | $1.09B |
| Total assets | $1.23B | $1.26B | $1.36B | $1.02B | $997M | $1.04B | $1.07B | $1.10B |
| Long-term debt | $340M | $340M | $340M | $118M | $118M | $118M | $117M | $117M |
| Total liabilities | $684M | $657M | $737M | $319M | $286M | $288M | $296M | $243M |
| Total equity | $543M | $603M | $626M | $696M | $711M | $754M | $777M | $857M |